» Articles » PMID: 38623390

The Burden and Management Competency of Cardiomyopathies in China: a Nationwide Survey Study

Abstract

Background: The public health burden of cardiomyopathies and competency in their management by health agencies in China are not well understood.

Methods: This study adopted a multi-stage sampling method for hospital selection. In the first stage, nationwide tertiary hospital recruitment was performed. As a result, 88 hospitals with the consent of the director of cardiology and access to an established electronic medical records system, were recruited. In the second stage, we sampled 66 hospitals within each geographic-economic stratification through a random sampling process. Data on (1) the outpatient and inpatient visits for cardiomyopathies between 2017 and 2021 and (2) the competency in the management of patients with cardiomyopathies, were collected. The competency of a hospital to provide cardiomyopathy care was evaluated using a specifically devised scale.

Findings: The outpatient and inpatient visits for cardiomyopathies increased between 2017 and 2021 by 38.6% and 33.0%, respectively. Most hospitals had basic facilities for cardiomyopathy assessment. However, access to more complex procedures was limited, and the integrated management pathway needs improvement. Only 4 (6.1%) of the 66 participating hospitals met the criteria for being designated as a comprehensive cardiomyopathy center, and only 29 (43.9%) could be classified as a primary cardiomyopathy center. There were significant variations in competency between hospitals with different administrative and economic levels.

Interpretation: The health burden of cardiomyopathies has increased significantly between 2017 and 2021 in China. Although most tertiary hospitals in China can offer basic cardiomyopathy care, more advanced facilities are not yet universally available. Moreover, inconsistencies in the management of cardiomyopathies across hospitals due to differing administrative and economic levels warrants a review of the nation allocation of medical resources.

Funding: This work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2023-I2M-1-001) and the National High Level Hospital Clinical Research Funding (2022-GSP-GG-17).

Citing Articles

[Clincial Research Progress in Using Magnetic Resonance Imaging to Assess Myocardial Fibrosis in Hypertrophic Cardiomyopathy].

Shi K, Yu S, Xia D, Guo Y, Yang Z Sichuan Da Xue Xue Bao Yi Xue Ban. 2025; 55(6):1357-1363.

PMID: 39990836 PMC: 11839347. DOI: 10.12182/20241160601.

References
1.
Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A . Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J. 2022; 43(45):4679-4693. PMC: 9712030. DOI: 10.1093/eurheartj/ehac543. View

2.
Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

3.
Lorenzini M, Norrish G, Field E, Ochoa J, Cicerchia M, Akhtar M . Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J Am Coll Cardiol. 2020; 76(5):550-559. PMC: 7397507. DOI: 10.1016/j.jacc.2020.06.011. View

4.
Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H . Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004; 116(1):14-8. DOI: 10.1016/j.amjmed.2003.05.009. View

5.
Zhong Q, Gao Y, Zheng X, Chen J, Masoudi F, Lu Y . Geographic Variation in Process and Outcomes of Care for Patients With Acute Myocardial Infarction in China From 2001 to 2015. JAMA Netw Open. 2020; 3(10):e2021182. PMC: 7584924. DOI: 10.1001/jamanetworkopen.2020.21182. View